Type Here to Get Search Results !

Covishield Vaccine Update: Serum India Vaccine Applied to People in Pune, know what is update







In the midst of the Corona epidemic, the world is slowly moving towards recovering from it. Scientists from many countries are getting success in preparing medicines and vaccines. Different types of vaccines are being developed in many countries. Russia and China have prepared the vaccine, on the other hand, in India, America, Britain, Germany etc. countries will soon be available. There are three vaccines going forward in India, one of which is Oxford University and AstraZeneca vaccine. The company is developing the vaccine in collaboration with Serum Institute of India. The Indian company Serum Institute of India is launching this vaccine in India under the name of Kovishield (AZD1222). The latest update on the vaccine is that the Phase-2 trial of this vaccine has started in Pune today. Volunteers have been given vaccine doses under the supervision of doctors.

In Pune, Maharashtra, the phase-2 trial of its phase-2 has started from Wednesday. According to the news, five people have been given the dose of this vaccine at Bharti Vidyapeeth Medical College and Hospital on Wednesday afternoon. According to doctors, if the result is positive, then around 300 to 350 people will be given this vaccine.

According to Dr. Sanjay Lalwani, Medical Director of the Medical College and Hospital of Bharti Vidyapeeth, Pune, RT-PCR screening and antibody testing were also done after screening the five persons selected for the trial. They hope that the trial of the vaccine will have positive results.

Maharashtra Minister Dr. Vishwajit Kadam said that five people have been given the first dose of wax at Bharti Astpal in Pune. All volunteers will be under medical supervision for the next two months.

The Serum Institute of India has tied up with the British-Swedish pharmaceutical firm AstraZeneca to produce one billion doses of the vaccine in the country. According to the report published in the medical journal The Lancet, this vaccine has proved to be completely safe and effective in the trials conducted so far.

It is known that after proving effective in the first and second phase trials conducted by Britain, its second and third phase human trials have also been allowed in India. The top drug regulator, the Drug Controller General of India, has approved Serum India in the country for a cardiac trial on August 3.

When the Covishield vaccine would be available, there were earlier reports that this vaccine would be available in the market after 73 days. But later the company made it clear that this is only speculative, not confirmed information. The Serum Institute has said that the company has received permission from the government to produce the vaccine, but for future use. The company has said that the vaccine will come into the market only when the trials are successful and get the approval from the regulatory agency.

According to reports, the trial of the third phase of this vaccine is expected to be completed by November. If the trial results are good and there are no side effects of the vaccine, then the vaccine will easily get regulatory approval and then the vaccine will be available for vaccination. It is expected that this vaccine will be available in the Indian market by the end of the year.




Post a Comment


Top Post Ad

Below Post Ad